OncoPro PD-L1 Circulating Tumor Cells Test
Revolutionary Liquid Biopsy for Cancer Immunotherapy Guidance
The OncoPro PD-L1 Circulating Tumor Cells Test represents a groundbreaking advancement in cancer diagnostics and personalized medicine. This innovative liquid biopsy test detects circulating tumor cells (CTCs) in the bloodstream and specifically analyzes their PD-L1 protein expression levels. PD-L1 (Programmed Death-Ligand 1) is a critical biomarker that plays a pivotal role in cancer’s ability to evade the immune system, making it a key target for modern immunotherapy treatments.
What Does This Test Measure?
The OncoPro PD-L1 CTC Test provides comprehensive analysis of:
- Circulating Tumor Cell Detection: Identifies and quantifies cancer cells circulating in the bloodstream
- PD-L1 Expression Analysis: Measures the level of PD-L1 protein on detected tumor cells
- Immunotherapy Response Prediction: Assesses likelihood of response to PD-1/PD-L1 inhibitor drugs
- Real-time Cancer Monitoring: Tracks disease progression and treatment effectiveness
Who Should Consider This Test?
This advanced diagnostic test is particularly beneficial for:
- Patients with advanced or metastatic cancers considering immunotherapy
- Individuals where traditional tissue biopsy is not feasible or safe
- Patients experiencing cancer progression despite standard treatments
- Those requiring ongoing monitoring of treatment response
- Individuals with cancers known to respond to immunotherapy (lung, melanoma, bladder, etc.)
- Patients seeking non-invasive alternatives to repeated tissue biopsies
Key Benefits of OncoPro PD-L1 CTC Testing
- Non-Invasive Procedure: Simple blood draw eliminates risks associated with tissue biopsies
- Real-time Monitoring: Provides current snapshot of cancer status and treatment response
- Personalized Treatment Guidance: Helps oncologists select the most effective immunotherapy options
- Comprehensive Tumor Analysis: Captures tumor heterogeneity across multiple metastatic sites
- Early Response Detection: Identifies treatment effectiveness sooner than traditional imaging
- Reduced Healthcare Costs: Minimizes need for expensive, invasive procedures
Understanding Your Test Results
Your OncoPro PD-L1 CTC test results will provide valuable insights into your cancer status and treatment options:
- High PD-L1 Expression: Indicates increased likelihood of response to immunotherapy drugs targeting the PD-1/PD-L1 pathway
- Low PD-L1 Expression: May suggest alternative treatment approaches or combination therapies
- CTC Count Changes: Decreasing CTC numbers typically indicate positive treatment response
- Dynamic Monitoring: Serial testing helps track treatment effectiveness over time
It’s essential to discuss your results with your oncologist, who will interpret them in the context of your specific cancer type, stage, and overall health status.
Test Pricing and Availability
| Test Name | Regular Price | Discount Price |
|---|---|---|
| OncoPro PD-L1 Circulating Tumor Cells Test | $1462 USD | $1316 USD |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our state-of-the-art facilities ensure consistent, high-quality testing services nationwide.
Take the Next Step in Your Cancer Care Journey
Don’t leave your treatment decisions to chance. The OncoPro PD-L1 Circulating Tumor Cells Test provides the critical information needed to make informed decisions about your cancer care. Our experienced team is ready to guide you through the testing process and help you access the most advanced diagnostic technology available.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or speak with our genetic counseling specialists. Take control of your cancer treatment with precision diagnostics that deliver actionable insights for better health outcomes.
